EZZ Life Science Holdings Ltd (EZZ) fair value: what the stock is really worth
As of Nov 9, 2026: fair value (intrinsic value) of EZZ Life Science Holdings Ltd stock A$0.48, price A$0.29, upside +65.5%, quality 48 out of 100. Rating: strongly undervalued. Calculated from audited financials with one of our 26 valuation models and 37 quality factors, updated daily.
69 individual criteria per stock, every one traceableSee the method →
Price vs Fair Value
White line = price, green steps = our fair value per fiscal year. As of Nov 4, 2026.
How to read this chart
60‑month range A$0.2551 – A$4.83 · fair‑value band A$0.3200 – A$0.6100 · the A$0.2900 price screens below the A$0.4800 fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). As of Nov 4, 2026.
Follow EZZ Life Science Holdings in your weekly email
Every Wednesday you see whether EZZ Life Science Holdings is on track or worth a review, plus price against fair value. Free, up to 3 stocks.
We send you a confirmation link. Unsubscribe with one click.
EZZ Life Science Holdings Limited engages in formulation, production, marketing, and sale of the health and wellbeing products in Australia, New Zealand, Mainland China, and South-East Asia. The company operates through two segments, Brought in Lines and Company Owned Products.
Show moreShow less
It is involved in the wholesale distribution of the EAORON branded skin care products to retailers; and direct-to-consumer distribution through e-commerce store. The company provides health and wellness products under the EZZ brand. It also offers its products online.
The company was incorporated in 2015 and is based in Lidcombe, Australia.
Stock analysis
EZZ Life Science Holdings Ltd (EZZ) currently trades at A$0.2900, while our model-based Fair Value estimate is A$0.4800, implying the stock looks roughly 40% undervalued today.
Show more
Valuation
How firm this estimate is: it rests on 1 models at a data quality of 96/100, which puts the data coverage at low.
Scenario range: A$0.3200 (bear) to A$0.6100 (bull), the price of A$0.2900 sits below it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.
Quality & growth
The Quality Score stands at 48/100 (below-average quality), in the Healthcare sector.
Expensive Growth: The company is growing, but growth may require heavy reinvestment or weak cash conversion.
EZZ Life Science Holdings Ltd reported revenue of A$46.3M in FY2025 versus A$15.0M in FY2021, a compound +32.5%/yr. Reported net income was −A$5.3M in FY2025.
Key figures
Market cap A$13.6M (≈ $9.4M) Micro · P/S ratio 0.32 · EPS (TTM) A$−0.1100 · Dividend yield 6.9% · Net margin −11.5% · Return on equity −20.3% · Return on assets (EBIT) 16.2% (5-year average) · Operating margin −30.3%.
Competitive moat
Our AI-assisted moat analysis scores the competitive advantage at 17 out of 100 (low confidence).
What moves the price
The share trades about 88% below its 52-week high and at its 52-week low, currently below its 200-day average.
For context, the median of 10 Healthcare peers we cover trades at 10% fair-value upside, at 66%, EZZ screens cheaper than that median.
Fair Value models
BearA$0.3200Fair Value A$0.4800BullA$0.6100
Price A$0.2900 · Upside +65.5%
Model ⓘEach model values the company its own way (discounted cash flow, earnings, assets, dividends). The fair value above starts from their evidence-weighted blend, not from a single model. In cyclical trough or peak years, after dilution or a stock split it is adjusted afterwards, so it can sit above or below the models.Bear ⓘBear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull ⓘBull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target. If a model's bull case is above four times its base value, the table shows that limit with a > sign (like the overall Bull above): beyond it no assumption holds.Coverage ⓘCoverage = how well-backed THIS model's estimate is for this stock (0–100): how complete and reliable its input data are, and how well the model fits the company. The final Fair Value is an evidence-weighted blend, so better-evidenced models count more. Green ≥70, amber 50–69, grey below 50.
Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card.38/100
The company is growing, but growth may require heavy reinvestment or weak cash conversion.
Revenue growth 1 year
−30.8%
Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+7.6%
Revenue growth 5 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+15.7%
Start year 2020 (pandemic)
Revenue growth 7 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+22.5%
’18
’19
’20
’21
’22
’23
’24
’25
Profit margin (trend) ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.
11.5% (2020) → −14.3% (2025)
What shareholders gained per year ⓘWe only publish this rate when it is defensible. Reason: fiscal 2025 is a loss year, no rate is defined from a loss
Compare EZZ Life Science Holdings Ltd with another stock
Price, fair value, quality and upside side by side.
Free, no sign-up
Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Biotechnology · 558 stocks
Beats the industry median on 5/9 measures
A mixed picture versus its industry peers.
Valuation
Quality Score48 · Above median
Fair Value upside+65.5% · Top 25%
Profitability
Return on assets−19.3% · Below median
Net margin (12 months)−11.5% · Below median
Operating margin (12 months)−30.3% · Bottom 25%
Growth and dividend
Revenue growth (quarter YoY)−49.5% · Bottom 25%
Dividend yield (12 months)6.9% · Top 25%
Valuation Multiplesvs Biotechnology median · lower = cheaper
For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.
Cite: Fair Value Calculator (2026). "EZZ Life Science Holdings Ltd Fair Value". https://www.fairvalue-calculator.com/stock/EZZ
Frequently asked questions
Is EZZ Life Science Holdings Ltd (EZZ) overvalued or undervalued?
As of Nov 4, 2026, our model estimates a fair value of A$0.4800 versus a price of A$0.2900, about +66% upside (undervalued).
What is the fair value of EZZ?
Our model-based fair value for EZZ Life Science Holdings Ltd is A$0.4800 (as of Nov 4, 2026), built from audited fundamentals. The current price: A$0.2900.
What is the quality score of EZZ?
EZZ Life Science Holdings Ltd has a Quality Score of 48/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for EZZ Life Science Holdings Ltd (EZZ)?
Our model-based price target is the fair value of A$0.4800 (as of Nov 4, 2026) from 1 valuation models. Cautious scenario A$0.3200, optimistic scenario A$0.6100. It is a calculation from audited fundamentals, not an analyst target.
What is the EZZ Life Science Holdings Ltd stock forecast for 2026?
Our models put fair value at A$0.4800, about +66% upside versus a price of A$0.2900 (undervalued). Cautious scenario A$0.3200, optimistic scenario A$0.6100. The calculation is refreshed regularly with new filings.
What is the revenue of EZZ Life Science Holdings Ltd (EZZ)?
EZZ Life Science Holdings Ltd reported trailing-twelve-month revenue of about A$46.3M (latest available figure, as of Nov 4, 2026).
Does EZZ Life Science Holdings Ltd pay a dividend?
EZZ Life Science Holdings Ltd currently shows a dividend yield of 6.90% relative to its recent price (as of Nov 4, 2026).
How much is the dividend of EZZ Life Science Holdings Ltd (EZZ) and when is the ex-dividend date?
EZZ Life Science Holdings Ltd pays a dividend of A$0.02 per share a year, a dividend yield of 6.9%. The last ex-dividend date was Nov 24, 2025. A dividend has been paid every year since at least 2021. Our assessment: Watch coverage. The dividend isn’t fully covered by free cash flow or earnings, part of it is funded from reserves or debt. Fine for now, but worth watching: if it stays uncovered, the dividend could be cut.
What is the intrinsic value of EZZ Life Science Holdings Ltd (EZZ)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For EZZ Life Science Holdings Ltd it is A$0.4800 per share (as of Nov 4, 2026), against a price of A$0.2900. It is the blended result of 1 valuation models in 1 family (Asset-Based).
Is EZZ Life Science Holdings Ltd stock overvalued or undervalued in 2026?
As of Nov 4, 2026, EZZ trades below its calculated fair value: price A$0.2900, fair value A$0.4800, a gap of about +66% (undervalued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of EZZ?
No. The price is what the market pays today (A$0.2900); the fair value is what the company's own numbers justify (A$0.4800). For EZZ Life Science Holdings Ltd the two are A$0.1900 per share apart. That gap is exactly why we show both numbers side by side.
How much is EZZ Life Science Holdings Ltd worth?
The market values EZZ Life Science Holdings Ltd at about A$13.6M (market capitalisation, as of Nov 4, 2026). Per share that is A$0.2900; our models calculate a fair value of A$0.4800 per share.
What do the bullish and bearish scenarios say about EZZ?
Our models span a range for EZZ Life Science Holdings Ltd: cautious scenario A$0.3200, base A$0.4800, optimistic A$0.6100 per share (as of Nov 4, 2026, price A$0.2900). The range comes from different growth and margin assumptions, not from analyst opinions.
How solid is the balance sheet of EZZ Life Science Holdings Ltd (EZZ)?
Balance-sheet figures for EZZ Life Science Holdings Ltd (as of Nov 4, 2026): return on equity −20.3%. They feed the Quality Score of 48/100, which measures business quality independently of the share price.
How far is EZZ from its 52-week high?
EZZ Life Science Holdings Ltd trades at A$0.2900, about 88% below its 52-week high of A$2.50 and at the low of A$0.2900 (as of Nov 9, 2026). Distance from the high says nothing about value: that is what the fair value of A$0.4800 is for.
Which stocks are comparable to EZZ Life Science Holdings Ltd?
From the same area (Healthcare) we also value Vertex Pharmaceuticals Incorporated, Regeneron Pharmaceuticals, Inc, CSL Limited, argenx SE, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is EZZ Life Science Holdings Ltd stock attractive at the current price?
The data as of Nov 4, 2026: price A$0.2900, calculated fair value A$0.4800 (+66%), Quality Score 48/100, from 1 models. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
How is the fair value of EZZ calculated?
We run EZZ Life Science Holdings Ltd through 1 models from 1 family: Asset-Based. Every model gets the same audited fundamentals; the fair value of A$0.4800 builds on their evidence-weighted average, with the spread shown as a cautious and an optimistic scenario.
Is it still worth investing in stocks now?
The global stock market currently sits 13.3% above its aggregate fair value. EZZ Life Science Holdings Ltd currently trades 40% below its own fair value, and the market average says nothing about that. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of EZZ Life Science Holdings Ltd (EZZ)?
The closing price on Nov 9, 2026 was A$0.2900. Our model-based fair value is A$0.4800, about +66% upside (undervalued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with EZZ Life Science Holdings Ltd right now?
The large discount to fair value meets weak quality (48/100). That raises the risk this is a value trap rather than a bargain. The price is below even our cautious bear case (A$0.3200). The market is more pessimistic than our downside scenario. The large gap to fair value rests on thin data (low evidence): fewer applicable models and a shorter history. Read it with extra caution. A fairly wide model range (A$0.3200 to A$0.6100) leaves room in how you read the outcome.
Key figures of EZZ Life Science Holdings Ltd
How large is the market capitalisation of EZZ Life Science Holdings Ltd (EZZ)?
The market capitalisation of EZZ Life Science Holdings Ltd is A$13.6M (≈ $9.4M). The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What is the P/S ratio of EZZ Life Science Holdings Ltd (EZZ)?
The price-to-sales ratio of EZZ Life Science Holdings Ltd is 0.32 (last twelve months). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.
What are the earnings per share of EZZ Life Science Holdings Ltd (EZZ)?
Earnings per share at EZZ Life Science Holdings Ltd are A$−0.1100. Earnings per share over the last twelve months: total profit spread across every single share.
What is the dividend yield of EZZ Life Science Holdings Ltd (EZZ)?
The dividend yield of EZZ Life Science Holdings Ltd is 6.9%. Yearly dividend relative to the share price. 3% pays 3 per 100 invested. Below: how much of profit is used for it.
What is the net margin of EZZ Life Science Holdings Ltd (EZZ)?
The net margin of EZZ Life Science Holdings Ltd is −11.5% (last twelve months). How much of every unit of revenue ends up as profit. 10% means 10 cents of profit per dollar of sales.
What is the return on equity of EZZ Life Science Holdings Ltd (EZZ)?
The return on equity (ROE) of EZZ Life Science Holdings Ltd is −20.3% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of EZZ Life Science Holdings Ltd (EZZ)?
On an EBIT basis the return on assets of EZZ Life Science Holdings Ltd is 16.2% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of EZZ Life Science Holdings Ltd (EZZ)?
The operating margin of EZZ Life Science Holdings Ltd is −30.3% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How fast is revenue growing at EZZ Life Science Holdings Ltd (EZZ)?
Revenue at EZZ Life Science Holdings Ltd is growing −49.5% versus a year earlier (3y avg +7.6%). How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.
How fast are earnings growing at EZZ Life Science Holdings Ltd (EZZ)?
Earnings per share at EZZ Life Science Holdings Ltd are growing −44.2% versus a year earlier. How much earnings per share grew versus a year earlier.
How much free cash flow does EZZ Life Science Holdings Ltd (EZZ) generate?
The free cash flow of EZZ Life Science Holdings Ltd is −A$8.8M (fiscal year 2025). The cash truly left after running and investing in the business, this is what pays dividends and buybacks.
How much net cash does EZZ Life Science Holdings Ltd (EZZ) hold?
EZZ Life Science Holdings Ltd holds more cash than debt, A$9.2M net (fiscal year 2025). The company holds more cash than debt, a safety cushion.
Free · no account needed
Watch EZZ Life Science Holdings Ltd in the live analysis
One click puts EZZ Life Science Holdings Ltd on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 27,000+ stock screener.
Thin data
Nov 4, 2026